Bicycle Therapeutics plc
BCYC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $814,906 | $643,510 | $877,956 | $1,525,508 |
| - Cash | $879,520 | $526,423 | $339,154 | $438,680 |
| + Debt | $9,493 | $44,956 | $44,325 | $44,337 |
| Enterprise Value | -$55,121 | $162,043 | $583,127 | $1,131,165 |
| Revenue | $35,275 | $26,976 | $14,463 | $11,697 |
| % Growth | 30.8% | 86.5% | 23.6% | – |
| Gross Profit | -$137,691 | -$129,520 | $14,463 | $11,697 |
| % Margin | -390.3% | -480.1% | 100% | 100% |
| EBITDA | -$164,892 | -$183,400 | -$107,208 | -$64,089 |
| % Margin | -467.4% | -679.9% | -741.3% | -547.9% |
| Net Income | -$169,031 | -$180,664 | -$112,717 | -$66,819 |
| % Margin | -479.2% | -669.7% | -779.3% | -571.2% |
| EPS Diluted | -2.9 | -5.08 | -3.8 | -2.67 |
| % Growth | 42.9% | -33.7% | -42.3% | – |
| Operating Cash Flow | -$164,724 | -$60,628 | -$86,111 | -$14,794 |
| Capital Expenditures | -$1,235 | -$2,929 | -$18,987 | -$2,030 |
| Free Cash Flow | -$165,959 | -$63,557 | -$105,098 | -$16,824 |